These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 7897379)

  • 1. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.
    Van Damme P; Thoelen S; Cramm M; De Groote K; Safary A; Meheus A
    J Med Virol; 1994 Dec; 44(4):446-51. PubMed ID: 7897379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A.
    Zuckerman JN; Kirkpatrick CT; Huang M
    J Travel Med; 1998 Mar; 5(1):18-22. PubMed ID: 9772311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity.
    Van Damme P; Matheï C; Thoelen S; Meheus A; Safary A; André FE
    J Med Virol; 1994 Dec; 44(4):435-41. PubMed ID: 7897376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later.
    Briem H; Safary A
    J Med Virol; 1994 Dec; 44(4):443-5. PubMed ID: 7897378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine.
    Maiwald H; Jilg W; Bock HL; Löscher T; Sonnenburg F
    Vaccine; 1997 Mar; 15(4):346-8. PubMed ID: 9141202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose-inactivated hepatitis A vaccination schedule for susceptible youngsters.
    Lee SD; Chan CY; Yu MI; Wang YJ; Lo KJ; Safary A
    Am J Gastroenterol; 1996 Jul; 91(7):1360-2. PubMed ID: 8677995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reactivity and immunogenicity of Havrix 360 vaccine for hepatitis A].
    Borcić B; Kovac S; Mihaljević I; Dobrovsak-Sourek V; Ljubicić M
    Lijec Vjesn; 1996; 118(7-8):162-4. PubMed ID: 8965633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.
    Van Herck K; Beutels P; Van Damme P; Beutels M; Van den Dries J; Briantais P; Vidor E
    J Med Virol; 2000 Jan; 60(1):1-7. PubMed ID: 10568755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years.
    Fan PC; Chang MH; Lee PI; Safary A; Lee CY
    Vaccine; 1998; 16(2-3):232-5. PubMed ID: 9607035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children.
    Castillo de Febres O; Chacon de Petrola M; Casanova de Escalona L; Naveda O; Naveda M; Estopinan M; Bordones G; Zambrano B; Garcia A; Dumas R
    Vaccine; 1999 Nov; 18(7-8):656-64. PubMed ID: 10547425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination.
    Totos G; Gizaris V; Papaevangelou G
    Vaccine; 1997 Aug; 15(11):1252-3. PubMed ID: 9286052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two immunization schedules with an inactivated hepatitis A vaccine (AvaximTM).
    Vidor E; Ratheau C; Briantais P; Vuillier D
    J Travel Med; 1998 Dec; 5(4):167-72. PubMed ID: 9876189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactogenicity and immunogenicity of three different lots of a hepatitis A vaccine.
    Theilmann L; Kallinowski B; Gmelin K; Hofmann F; Scheiermann N; Wohland B; Stickl H; Maiwald H; Moriabadi FK; Bock HL
    Vaccine; 1992; 10 Suppl 1():S132-4. PubMed ID: 1335644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children.
    Newcomer W; Rivin B; Reid R; Moulton LH; Wolff M; Croll J; Johnson C; Brown L; Nalin D; Santosham M
    Pediatr Infect Dis J; 1994 Jul; 13(7):640-2. PubMed ID: 7970954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study.
    Goilav C; Zuckerman J; Lafrenz M; Vidor E; Lauwers S; Ratheau C; Benichou G; Zuckerman A
    J Med Virol; 1995 Jul; 46(3):287-92. PubMed ID: 7561805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults.
    Bruguera M; Bayas JM; Vilella A; Tural C; González A; Vidal J; Dal-Ré R; Salleras L
    Vaccine; 1996 Oct; 14(15):1407-11. PubMed ID: 8994314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis A antibody titres after infection and immunization: implications for passive and active immunization.
    Zaaijer HL; Leentvaar-Kuijpers A; Rotman H; Lelie PN
    J Med Virol; 1993 May; 40(1):22-7. PubMed ID: 8515245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children.
    Kanra G; Yalçin SS; Ceyhan M; Yurdakök K
    Turk J Pediatr; 2000; 42(2):105-8. PubMed ID: 10936974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years.
    Van Herck K; Van Damme P; Collard F; Thoelen S
    Scand J Gastroenterol; 1999 Dec; 34(12):1236-40. PubMed ID: 10636072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.